PFIZER reports Q1 2010 results reaffirming 2010 financial guidance, Pfizer Inc

Release Date: 2010-05-04

Pfizer posts Q1 2010 Revenues of $16.8 Billion; the reported diluted EPS(1) is $0.25 and adjusted diluted EPS(2) is $0.60.

2010 Financial Guidance and 2012 Diluted EPS Target Ranges reaffirmed. Solid progress on the Wyeth Integration continued.
Pfizer Inc. (NYSE: PFE) reports financial results for Q1 2010. Since the acquisition of Wyeth was completed on October 15, 2009, legacy Wyeth operations are reflected in first-quarter 2010 results, but not in first-quarter 2009 results.

First-quarter 2010 revenues were $16.8 billion, an increase of 54% compared with $10.9 billion in the year-ago quarter. Revenues for first-quarter 2010 compared with the year-ago quarter were favorably impacted by $5.3 billion, or 48%, due to the addition of the legacy Wyeth
products, and $733 million, or 7%, due to foreign exchange. Revenues were unfavorably impacted by $137 million, or 1%, due to legacy Pfizer products. Revenues for first-quarter 2010 reflect a reduction of $56 million due to the recently enacted U.S. healthcare legislation. For first-quarter 2010, U.S. revenues were $7.3 billion, an increase of 47% compared with the year-ago quarter. International revenues were $9.4 billion, an increase of 60% compared with the prior-year quarter, which reflected 48% operational growth and a 12% favorable impact of foreign exchange. U.S. revenues represented 44% of total revenues in first-quarter 2010 compared with 46% in the year-ago quarter, while international revenues represented 56% of total revenues in first-quarter 2010 compared with 54% in the year-ago quarter.
Type: NORMAL
Company: Pfizer Inc
Country: 美国
 
This website requires Flash Player 9 or later. If you can not view this site you probably need to update your system with this plug-in for your browser.